Patients with CD36 deficiency are associated with enhanced atherosclerotic cardiovascular diseases

Miyako Yuasa-Kawase, Daisaku Masuda, Taiji Yamashita, Ryota Kawase, Hajime Nakaoka, Miwako Inagaki, Kazuhiro Nakatani, Kazumi Tsubakio-Yamamoto, Tohru Ohama, Akifumi Matsuyama, Makoto Nishida, Masato Ishigami, Toshiharu Kawamoto, Issei Komuro, Shizuya Yamashita

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Aim: The clustering of dyslipidemia, impaired glucose tolerance and hypertension increases the morbidity and mortality from cardiovascular events. A class B scavenger receptor, CD36, is a receptor for oxidized LDL and a transporter of long-chain fatty acids. Because of the impaired uptake of oxidized LDL in CD36-deficient macrophages and from the results of CD36 knockout mice, CD36 deficiency (CD36-D) was supposed to be associated with reduced risks for coronary artery disease (CAD); however, CD36-D patients are often accompanied by a clustering of coronary risk factors. The current study aimed to investigate the morbidity and severity of cardiovascular diseases in CD36-D patients. Methods: By screening for CD36 antigen on platelets and monocytes using FACS or the absent myocardial accumulation of 123 I-BMIPP by scintigraphy, 40 patients with type I CD36-D were collected, the morbidity of CAD and their features of atherosclerotic cardiovascular diseases were observed. Screening for CD36-D in both CAD patients (n = 319) and healthy subjects (n = 1,239) were underwent. Results: The morbidity of CAD was significantly higher in CD36-D patients than in the general population; 50% of patients (20 out of 40) had CAD identified by BMIPP scintigraphy and 37.5% (3 out of 8) by FACS screening, respectively. Three representative CD36-D cases demonstrated severe CAD and atherosclerosis. The frequency of CD36-D was three times higher in CAD patients than in healthy subjects (0.9% vs 0.3%, p<0.0001). Conclusion: The morbidity of CAD is significantly higher in CD36-D patients suffering from severe atherosclerosis, implying that the status of CD36-D might be atherogenic.

Original languageEnglish
Pages (from-to)263-275
Number of pages13
JournalJournal of Atherosclerosis and Thrombosis
Volume19
Issue number3
DOIs
Publication statusPublished - 02-04-2012

Fingerprint

Cardiovascular Diseases
Coronary Artery Disease
Morbidity
Screening
Radionuclide Imaging
Cluster Analysis
Class B Scavenger Receptors
Healthy Volunteers
Oxidized LDL Receptors
Platelet Glycoprotein IV Deficiency
CD36 Antigens
Glucose Intolerance
Macrophages
Dyslipidemias
Platelets
Knockout Mice
Monocytes
Atherosclerosis
Fatty Acids
Blood Platelets

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine
  • Biochemistry, medical

Cite this

Yuasa-Kawase, M., Masuda, D., Yamashita, T., Kawase, R., Nakaoka, H., Inagaki, M., ... Yamashita, S. (2012). Patients with CD36 deficiency are associated with enhanced atherosclerotic cardiovascular diseases. Journal of Atherosclerosis and Thrombosis, 19(3), 263-275. https://doi.org/10.5551/jat.10603
Yuasa-Kawase, Miyako ; Masuda, Daisaku ; Yamashita, Taiji ; Kawase, Ryota ; Nakaoka, Hajime ; Inagaki, Miwako ; Nakatani, Kazuhiro ; Tsubakio-Yamamoto, Kazumi ; Ohama, Tohru ; Matsuyama, Akifumi ; Nishida, Makoto ; Ishigami, Masato ; Kawamoto, Toshiharu ; Komuro, Issei ; Yamashita, Shizuya. / Patients with CD36 deficiency are associated with enhanced atherosclerotic cardiovascular diseases. In: Journal of Atherosclerosis and Thrombosis. 2012 ; Vol. 19, No. 3. pp. 263-275.
@article{f6bcff0120fb4c66a2e999fbe1967864,
title = "Patients with CD36 deficiency are associated with enhanced atherosclerotic cardiovascular diseases",
abstract = "Aim: The clustering of dyslipidemia, impaired glucose tolerance and hypertension increases the morbidity and mortality from cardiovascular events. A class B scavenger receptor, CD36, is a receptor for oxidized LDL and a transporter of long-chain fatty acids. Because of the impaired uptake of oxidized LDL in CD36-deficient macrophages and from the results of CD36 knockout mice, CD36 deficiency (CD36-D) was supposed to be associated with reduced risks for coronary artery disease (CAD); however, CD36-D patients are often accompanied by a clustering of coronary risk factors. The current study aimed to investigate the morbidity and severity of cardiovascular diseases in CD36-D patients. Methods: By screening for CD36 antigen on platelets and monocytes using FACS or the absent myocardial accumulation of 123 I-BMIPP by scintigraphy, 40 patients with type I CD36-D were collected, the morbidity of CAD and their features of atherosclerotic cardiovascular diseases were observed. Screening for CD36-D in both CAD patients (n = 319) and healthy subjects (n = 1,239) were underwent. Results: The morbidity of CAD was significantly higher in CD36-D patients than in the general population; 50{\%} of patients (20 out of 40) had CAD identified by BMIPP scintigraphy and 37.5{\%} (3 out of 8) by FACS screening, respectively. Three representative CD36-D cases demonstrated severe CAD and atherosclerosis. The frequency of CD36-D was three times higher in CAD patients than in healthy subjects (0.9{\%} vs 0.3{\%}, p<0.0001). Conclusion: The morbidity of CAD is significantly higher in CD36-D patients suffering from severe atherosclerosis, implying that the status of CD36-D might be atherogenic.",
author = "Miyako Yuasa-Kawase and Daisaku Masuda and Taiji Yamashita and Ryota Kawase and Hajime Nakaoka and Miwako Inagaki and Kazuhiro Nakatani and Kazumi Tsubakio-Yamamoto and Tohru Ohama and Akifumi Matsuyama and Makoto Nishida and Masato Ishigami and Toshiharu Kawamoto and Issei Komuro and Shizuya Yamashita",
year = "2012",
month = "4",
day = "2",
doi = "10.5551/jat.10603",
language = "English",
volume = "19",
pages = "263--275",
journal = "Journal of Atherosclerosis and Thrombosis",
issn = "1340-3478",
publisher = "Japan Atherosclerosis Society",
number = "3",

}

Yuasa-Kawase, M, Masuda, D, Yamashita, T, Kawase, R, Nakaoka, H, Inagaki, M, Nakatani, K, Tsubakio-Yamamoto, K, Ohama, T, Matsuyama, A, Nishida, M, Ishigami, M, Kawamoto, T, Komuro, I & Yamashita, S 2012, 'Patients with CD36 deficiency are associated with enhanced atherosclerotic cardiovascular diseases', Journal of Atherosclerosis and Thrombosis, vol. 19, no. 3, pp. 263-275. https://doi.org/10.5551/jat.10603

Patients with CD36 deficiency are associated with enhanced atherosclerotic cardiovascular diseases. / Yuasa-Kawase, Miyako; Masuda, Daisaku; Yamashita, Taiji; Kawase, Ryota; Nakaoka, Hajime; Inagaki, Miwako; Nakatani, Kazuhiro; Tsubakio-Yamamoto, Kazumi; Ohama, Tohru; Matsuyama, Akifumi; Nishida, Makoto; Ishigami, Masato; Kawamoto, Toshiharu; Komuro, Issei; Yamashita, Shizuya.

In: Journal of Atherosclerosis and Thrombosis, Vol. 19, No. 3, 02.04.2012, p. 263-275.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Patients with CD36 deficiency are associated with enhanced atherosclerotic cardiovascular diseases

AU - Yuasa-Kawase, Miyako

AU - Masuda, Daisaku

AU - Yamashita, Taiji

AU - Kawase, Ryota

AU - Nakaoka, Hajime

AU - Inagaki, Miwako

AU - Nakatani, Kazuhiro

AU - Tsubakio-Yamamoto, Kazumi

AU - Ohama, Tohru

AU - Matsuyama, Akifumi

AU - Nishida, Makoto

AU - Ishigami, Masato

AU - Kawamoto, Toshiharu

AU - Komuro, Issei

AU - Yamashita, Shizuya

PY - 2012/4/2

Y1 - 2012/4/2

N2 - Aim: The clustering of dyslipidemia, impaired glucose tolerance and hypertension increases the morbidity and mortality from cardiovascular events. A class B scavenger receptor, CD36, is a receptor for oxidized LDL and a transporter of long-chain fatty acids. Because of the impaired uptake of oxidized LDL in CD36-deficient macrophages and from the results of CD36 knockout mice, CD36 deficiency (CD36-D) was supposed to be associated with reduced risks for coronary artery disease (CAD); however, CD36-D patients are often accompanied by a clustering of coronary risk factors. The current study aimed to investigate the morbidity and severity of cardiovascular diseases in CD36-D patients. Methods: By screening for CD36 antigen on platelets and monocytes using FACS or the absent myocardial accumulation of 123 I-BMIPP by scintigraphy, 40 patients with type I CD36-D were collected, the morbidity of CAD and their features of atherosclerotic cardiovascular diseases were observed. Screening for CD36-D in both CAD patients (n = 319) and healthy subjects (n = 1,239) were underwent. Results: The morbidity of CAD was significantly higher in CD36-D patients than in the general population; 50% of patients (20 out of 40) had CAD identified by BMIPP scintigraphy and 37.5% (3 out of 8) by FACS screening, respectively. Three representative CD36-D cases demonstrated severe CAD and atherosclerosis. The frequency of CD36-D was three times higher in CAD patients than in healthy subjects (0.9% vs 0.3%, p<0.0001). Conclusion: The morbidity of CAD is significantly higher in CD36-D patients suffering from severe atherosclerosis, implying that the status of CD36-D might be atherogenic.

AB - Aim: The clustering of dyslipidemia, impaired glucose tolerance and hypertension increases the morbidity and mortality from cardiovascular events. A class B scavenger receptor, CD36, is a receptor for oxidized LDL and a transporter of long-chain fatty acids. Because of the impaired uptake of oxidized LDL in CD36-deficient macrophages and from the results of CD36 knockout mice, CD36 deficiency (CD36-D) was supposed to be associated with reduced risks for coronary artery disease (CAD); however, CD36-D patients are often accompanied by a clustering of coronary risk factors. The current study aimed to investigate the morbidity and severity of cardiovascular diseases in CD36-D patients. Methods: By screening for CD36 antigen on platelets and monocytes using FACS or the absent myocardial accumulation of 123 I-BMIPP by scintigraphy, 40 patients with type I CD36-D were collected, the morbidity of CAD and their features of atherosclerotic cardiovascular diseases were observed. Screening for CD36-D in both CAD patients (n = 319) and healthy subjects (n = 1,239) were underwent. Results: The morbidity of CAD was significantly higher in CD36-D patients than in the general population; 50% of patients (20 out of 40) had CAD identified by BMIPP scintigraphy and 37.5% (3 out of 8) by FACS screening, respectively. Three representative CD36-D cases demonstrated severe CAD and atherosclerosis. The frequency of CD36-D was three times higher in CAD patients than in healthy subjects (0.9% vs 0.3%, p<0.0001). Conclusion: The morbidity of CAD is significantly higher in CD36-D patients suffering from severe atherosclerosis, implying that the status of CD36-D might be atherogenic.

UR - http://www.scopus.com/inward/record.url?scp=84859059631&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859059631&partnerID=8YFLogxK

U2 - 10.5551/jat.10603

DO - 10.5551/jat.10603

M3 - Article

C2 - 22075538

AN - SCOPUS:84859059631

VL - 19

SP - 263

EP - 275

JO - Journal of Atherosclerosis and Thrombosis

JF - Journal of Atherosclerosis and Thrombosis

SN - 1340-3478

IS - 3

ER -